Literature DB >> 18452073

Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon-alpha.

Michael Robert Humphreys, Maria Cino, Ian Quirt, David Barth, Vishal Kukreti.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452073     DOI: 10.1080/10428190802087488

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  5 in total

Review 1.  Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.

Authors:  Meenakshi Bewtra; James D Lewis
Journal:  Expert Rev Clin Immunol       Date:  2010-07       Impact factor: 4.473

2.  Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.

Authors:  Mariko Yabe; L Jeffrey Medeiros; Yahya Daneshbod; Masoud Davanlou; Carlos E Bueso-Ramos; Elisa J Moran; Ken H Young; Roberto N Miranda
Journal:  Ann Diagn Pathol       Date:  2016-10-18       Impact factor: 2.090

Review 3.  Hepatosplenic T-cell lymphoma in a patient with Crohn's disease.

Authors:  Florian Beigel; Matthias Jürgens; Cornelia Tillack; Marion Subklewe; Doris Mayr; Burkhard Göke; Stephan Brand; Thomas Ochsenkühn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07       Impact factor: 46.802

4.  Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.

Authors:  Saranya A Selvaraj; Elizabeth Chairez; Lisa M Wilson; Mark Lazarev; Eric B Bass; Susan Hutfless
Journal:  Syst Rev       Date:  2013-07-05

5.  Hepatosplenic T-cell lymphoma in a 47-year-old Crohn's disease patient on thiopurine monotherapy.

Authors:  Maartje M van de Meeberg; Lauranne A A P Derikx; Harm A M Sinnige; Peet Nooijen; D Lucette Schipper; Loes H C Nissen
Journal:  World J Gastroenterol       Date:  2016-12-21       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.